390 related articles for article (PubMed ID: 31332076)
1. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
Monti D; Mazzantini D; Tampucci S; Vecchione A; Celandroni F; Burgalassi S; Ghelardi E
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
[TBL] [Abstract][Full Text] [Related]
2. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
3. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
4. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Tampucci S; Mailland F
Br J Dermatol; 2011 Jul; 165(1):99-105. PubMed ID: 21410668
[TBL] [Abstract][Full Text] [Related]
5. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
Matsuda Y; Sugiura K; Hashimoto T; Ueda A; Konno Y; Tatsumi Y
PLoS One; 2016; 11(7):e0159661. PubMed ID: 27441843
[TBL] [Abstract][Full Text] [Related]
6. Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.
Togni G; Mailland F
J Drugs Dermatol; 2010 May; 9(5):525-30. PubMed ID: 20480796
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimycotic activity and nail permeation models of a piroctone olamine (octopirox) containing transungual water soluble technology.
Dubini F; Bellotti MG; Frangi A; Monti D; Saccomani L
Arzneimittelforschung; 2005; 55(8):478-83. PubMed ID: 16149717
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Täuber A; Müller-Goymann CC
Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents.
Hur MS; Park M; Jung WH; Lee YW
Mycoses; 2019 Mar; 62(3):291-297. PubMed ID: 30427072
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
[TBL] [Abstract][Full Text] [Related]
12. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
Iwata A; Watanabe Y; Kumagai N; Katafuchi-Nagashima M; Sugiura K; Pillai R; Tatsumi Y
Antimicrob Agents Chemother; 2014 Aug; 58(8):4920-2. PubMed ID: 24867968
[TBL] [Abstract][Full Text] [Related]
14.
Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
[TBL] [Abstract][Full Text] [Related]
15. Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against Trichophyton rubrum in vitro.
Lusiana ; Reichl S; Müller-Goymann CC
Eur J Pharm Biopharm; 2013 Aug; 84(3):599-605. PubMed ID: 23419812
[TBL] [Abstract][Full Text] [Related]
16. [Affinity of Luliconazole to Keratin Prepared from Healthy Human Nailand Porcine Hoof].
Hasuko M; Toga T; Tsunemitsu T; Matsumoto T; Koga H; Hirano H; Tsuboi R
Med Mycol J; 2016; 57(1):J7-12. PubMed ID: 26936352
[TBL] [Abstract][Full Text] [Related]
17. Preparation and
Lee BC; Pangeni R; Na J; Koo KT; Park JW
Drug Deliv; 2019 Dec; 26(1):1167-1177. PubMed ID: 31738083
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
Kawai M
Med Mycol J; 2019; 60(3):71-74. PubMed ID: 31474693
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis].
Shimamura T; Miyamae A; Imai A; Hirayanagi K; Iwanaga T; Kubota N; Shibuya K
Med Mycol J; 2016; 57(4):J141-J147. PubMed ID: 27904059
[TBL] [Abstract][Full Text] [Related]
20. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
